Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

CMS Guidance Makes It Easier for Pharmacies to Access Part D Plans' Terms and Conditions


August 24, 2015

Centers for Medicare and Medicaid (CMS) recently issued guidance setting its expectation that Medicare Part D sponsors make their standard contracting terms and conditions available to requesting pharmacies no later than September 15 of the year preceding the benefit year.1 Requested terms and conditions should be provided to pharmacies within two business days of the request. If a sponsor requires a pharmacy to execute a confidentiality agreement before receiving the terms and conditions, that confidentiality agreement must be provided to the pharmacy within two business days of the request. The terms and conditions must then be provided within two business days of the sponsor's receipt of the confidentiality agreement. Also, sponsors are directed to clearly identify the avenue through which interested pharmacies should make their request (e.g., phone number, e-mail address, website).

CMS indicates that the guidance was prompted by recent reports it received from pharmacies describing issues with sponsors' contracting processes, including the transparency and timing. CMS reasoned that because sponsors should have "standard terms and conditions readily available by September 15, there is no justification for a delay in responding to a pharmacy's AWP [("any willing pharmacy")] request made after that date." CMS warned that sponsors should not cause any undue delay in executing "agreements with eligible and interested pharmacies that would in effect discourage pharmacies from pursuing an AWP contract." The guidance does not change the sponsor's ability to ask pharmacies to demonstrate they are qualified to meet the plan sponsors' standard terms and conditions before executing the contract.

1 CMS Compliance with Any Willing Pharmacy (AWP) Requirements, August 13, 2015 available at

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.